Author

P. L. Moore

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Organism:human· 4 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1

Frequent Co-Authors

P. Kgagudi· 5 shared B. E. Lambson· 4 shared L. Morris· 3 shared S. I. Richardson· 3 shared B. Oosthuysen· 2 shared C. Scheepers· 2 shared F. Ayres· 2 shared J. N. Bhiman· 2 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

P. Kgagudi

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Development of LIBRA-seq for the Guinea Pig Model System as a Tool for the Evaluation of Antibody Responses to Multivalent HIV-1 Vaccines

M. J. Vukovich, N. Raju, P. Kgagudi, N. P. Manamela, A. A. Abu-Shmais, K. R. Gripenstraw, P. T. Wasdin, S. Shen, B. Dwyer, J. Akoad, R. M. Lynch, D. C. Montefiori, S. I. Richardson, P. L. Moore, I. S. Georgiev

This paper evaluates multivalent HIV-1 Env immunization strategies in guinea pigs and adapts LIBRA-seq for antibody discovery, finding optimal cocktail sizes and identifying public clonotypes.

bioRxiv · Sep 25, 2023Immunology

Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms

T. Moyo-Gwete, C. Scheepers, Z. Makhado, P. Kgagudi, N. B. Mzindle, R. Ziki, S. Madzorera, N. P. Manamela, F. Ayres, B. E. Lambson, S. I. Richardson, L. Morris, P. L. Moore

This study investigates how different isotypes of the same HIV-neutralizing antibody achieve enhanced neutralization potency through distinct mechanisms involving hinge and CH1 regions.

bioRxiv · Aug 17, 2022 · PreprintImmunology

Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages

J. N. Bhiman, S. I. Richardson, B. E. Lambson, P. Kgagudi, N. Mzindle, H. Kaldine, C. Crowther, G. Gray, L.-G. Bekker, A. Koen, L. Fairlie, L. Fouche, Q. Bhorat, K. Dheda, M. Tameris, , P. L. Moore

This study evaluates the neutralizing antibody response to NVX-CoV2373 against Omicron sub-lineages after two or three doses, showing improved neutralization with a third dose.

bioRxiv · Jul 14, 2022 · PreprintImmunology

Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies

C. Scheepers, P. Kgagudi, N. Mzindle, E. S. Gray, T. Moyo-Gwete, B. E. Lambson, B. Oosthuysen, B. Mabvakure, N. J. Garrett, S. S. A. Karim, L. Morris, P. L. Moore

This study compares three HIV MPER-targeting antibodies, showing that CAP206-CH12's dependence on a variable residue limits its neutralization breadth, unlike the conserved residue reliance of 4E10 and VRC42.01.

bioRxiv · Mar 18, 2022Immunology

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

C. K. Wibmer, F. Ayres, T. Hermanus, M. Madzivhandila, P. Kgagudi, B. Oosthuysen, B. E. Lambson, T. de Oliveira, M. Vermeulen, K. van den Berg, T. Rossouw, M. Boswell, V. Ueckermann, S. Meiring, A. von Gottberg, , P. L. Moore

This study shows that SARS-CoV-2 501Y.V2 pseudovirus escapes neutralization by South African convalescent plasma but not binding, suggesting potential for reinfection and reduced vaccine efficacy.

bioRxiv · Jan 18, 2021Immunology